Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger CCHC domain-containing protein 17 (ZCCHC17) is a highly conserved nucleolar protein characterized by an S1 RNA-binding region and a CCHC-type zinc finger motif; it is predominantly expressed in the nucleolus where it is involved in ribosome maturation and biogenesis. ZCCHC17 interacts with splicing factors and is a negative regulator of rRNA transcription via interference with upstream binding factor (UBF) on rDNA promoters, leading to reduced pre-rRNA synthesis and nucleolar stress when overexpressed. In neurons, ZCCHC17 plays a critical role in regulating synaptic gene expression and maintaining synaptic protein balance; its reduced expression correlates with cognitive decline and tau pathology in Alzheimer's disease, making it a novel therapeutic target for enhancing cognitive resilience. The protein is a core component of the 60S ribosomal subunit, impacts mRNA quality control, and may regulate splicing and export of poly(A)+ RNA in the nucleus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger CCHC domain-containing protein 17 (ZCCHC17).